Frontiers in Oncology (Mar 2020)
Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 Pathway
- Dongli Yue,
- Dongli Yue,
- Daiqun Zhang,
- Xiaojuan Shi,
- Shasha Liu,
- Anqi Li,
- Dong Wang,
- Dong Wang,
- Guohui Qin,
- Guohui Qin,
- Yu Ping,
- Yamin Qiao,
- Yamin Qiao,
- Xinfeng Chen,
- Xinfeng Chen,
- Feng Wang,
- Renyin Chen,
- Song Zhao,
- Lidong Wang,
- Yi Zhang,
- Yi Zhang,
- Yi Zhang
Affiliations
- Dongli Yue
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Dongli Yue
- Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Daiqun Zhang
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Xiaojuan Shi
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Shasha Liu
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Anqi Li
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Dong Wang
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Dong Wang
- Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Guohui Qin
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Guohui Qin
- Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Yu Ping
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Yamin Qiao
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Yamin Qiao
- Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Xinfeng Chen
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Xinfeng Chen
- Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Feng Wang
- Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Renyin Chen
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Song Zhao
- Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Lidong Wang
- Henan Key Laboratory for Esophageal Cancer Research and State Key Laboratory for Esophageal Cancer Prevention & Treatment of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Yi Zhang
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Yi Zhang
- School of Life Sciences, Zhengzhou University, Zhengzhou, China
- Yi Zhang
- Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, China
- DOI
- https://doi.org/10.3389/fonc.2020.00311
- Journal volume & issue
-
Vol. 10
Abstract
Esophageal squamous cell carcinoma (ESCC) is one of the most prevalent cancers worldwide. Recent studies have shown that cancer stem cells (CSCs) are present in ESCC, are thought to lead to aggressive tumor behavior and the prognosis. The CXC chemokine receptor 4 (CXCR4), is regarded as a putative CSCs marker in various malignancies. Here, we demonstrate that CXCR4 played a key role in ESCC progression and CXCR4 positive ESCC cells possessed stem-like properties. Furthermore, the anti-malarial agent chloroquine (CQ) targeted CXCR4-positive ESCC cells via STAT3 pathway. Therefore, CQ with anti-CSCs effects may be an effective adjunct to current ESCC chemotherapy regimens.
Keywords
